Specific changes in the expression of imprinted genes in prostate cancer - Implications for cancer progression and epigenetic regulation

Asian Journal of Andrology

Volumn 14, Issue 3, 2012, Pages 436-450

  Ribarska, Teodora ^a   Bastian, Klaus Marius ^a   Koch, Annemarie ^a   Schulz, Wolfgang A ^a  

^a HEINRICH HEINE UNIVERSITY   (Germany)

Author keywords

androgen signalling; imprinted genes; loss of imprinting; PI3K signalling; prostate cancer

Indexed keywords

ANDROGEN; NECDIN; PHOSPHATIDYLINOSITOL 3 KINASE; PROTEIN KINASE B; SOMATOMEDIN B; TRANSCRIPTION FACTOR EZH2;

CANCER GROWTH; CARCINOGENESIS; CDKN1C GENE; DLK1 GENE; DNA METHYLATION; EPIGENETICS; GENE; GENE EXPRESSION; GENE INACTIVATION; GENE OVEREXPRESSION; GENETIC REGULATION; GENOME IMPRINTING; GNAS GENE; H19 GENE; HISTONE MODIFICATION; HUMAN; HYMAI GENE; IGF2 GENE; INPP5F GENE; MEG3 GENE; NDN GENE; NESP55 GENE; PEG10 GENE; PEG3 GENE; PLAGL1 GENE; PROSTATE CANCER; REVIEW; SGCE GENE; SIGNAL TRANSDUCTION; SNRPN GENE; ZAC1 GENE;

DISEASE PROGRESSION; DNA METHYLATION; DNA-BINDING PROTEINS; EPIGENESIS, GENETIC; GENE EXPRESSION REGULATION, NEOPLASTIC; GENE SILENCING; GENOMIC IMPRINTING; HUMANS; INSULIN-LIKE GROWTH FACTOR II; MALE; PHOSPHATIDYLINOSITOL 3-KINASES; POLYCOMB REPRESSIVE COMPLEX 2; PROGNOSIS; PROSTATIC NEOPLASMS; PROTO-ONCOGENE PROTEINS C-AKT; TRANSCRIPTION FACTORS;

EID: 84860856852     PISSN: 1008682X     EISSN: 17457262     Source Type: Journal    
DOI: 10.1038/aja.2011.160     Document Type: Review

References (261)

1. Kumar-Sinha C, Tomlins SA, Chinnaiyan AM. Recurrent gene fusions in prostate cancer. Nat Rev Cancer 2008; 8: 497-511.
2. Assinder SJ, Dong Q, Kovacevic Z, Richardson DR. The TGF-beta, PI3K/Akt and PTEN pathways: Established and proposed biochemical integration in prostate cancer. Biochem J 2009; 417: 411-421.
3. Lin HK, Hu YC, Lee DK, Chang C. Regulation of androgen receptor signaling by PTEN (phosphatase and tensin homolog deleted on chromosome 10) tumor suppressor through distinct mechanisms in prostate cancer cells. Mol Endocrinol 2004; 18: 2409-2423. (Pubitemid 39335977)
4. Kaarbo M, Mikkelsen OL, Malerod L, Qu S, Lobert VH et al. PI3K-AKT-mTOR pathway is dominant over androgen receptor signaling in prostate cancer cells. Cell Oncol 2010; 32: 11-27.
5. Mulholland DJ, Tran LM, Li Y, Cai H, Morim A et al. Cell autonomous role of PTEN in regulating castration-resistant prostate cancer growth. Cancer Cell 2011; 19: 792-804.
6. Yu J, Mani RS, Cao Q, Brenner CJ, Cao X et al. An integrated network of androgen receptor, polycomb, and TMPRSS2-ERG gene fusions in prostate cancer progression. Cancer Cell 2010; 17: 443-454.
7. Nelson WG, de Marzo AM, Yegnasubramanian S. Epigenetic alterations in human prostate cancers. Endocrinology 2009; 150: 3991-4002.
8. Schulz WA, Hoffmann MJ. Epigenetic mechanisms in the biology of prostate cancer. Semin Cancer Biol 2009; 19: 172-180.
9. Hoque MO. DNA methylation changes in prostate cancer: Current developments and future clinical implementation. Expert Rev Mol Diagn 2009; 9: 243-257.
10. Seligson DB, Horvath S, Shi T, Yu H, Tze S et al. Global histone modification patterns predict risk of prostate cancer recurrence. Nature 2005; 435: 1262-1266. (Pubitemid 40943093)
11. Florl AR, Steinhoff C, Muller M, Seifert HH, Hader C et al. Coordinate hypermethylation at specific genes in prostate carcinoma precedes LINE-1 hypomethylation. Br J Cancer 2004; 91: 985-994. (Pubitemid 39273795)
12. Yegnasubramanian S, Kowalski J, Gonzalgo ML, Zahurak M, Piantadosi S et al. Hypermethylation of CpG islands in primary and metastatic human prostate cancer. Cancer Res 2004; 64: 1975-1986. (Pubitemid 38339443)
13. Park JY. Promoter hypermethylation in prostate cancer. Cancer Control 2010; 17: 245-255.
14. Lee WH, Morton RA, Epstein JI, Brooks JD, Campbell PA et al. Cytidine methylation of regulatory sequences near the pi-class glutathione S-Transferase gene accompanies human prostatic carcinogenesis. Proc Natl Acad Sci USA 1994; 91: 11733-7. (Pubitemid 24356419)
15. Weiss G, Cottrell S, Distler J, Schatz P, Kristiansen G et al. DNA methylation of the PITX2 gene promoter region is a strong independent prognostic marker of biochemical recurrence in patients with prostate cancer after radical prostatectomy. J Urol 2009; 181: 1678-1685.
16. Vanaja DK, Grossmann ME, Cheville JC, Gazi MH, Gong A et al. PDLIM4, an actin binding protein, suppresses prostate cancer cell growth. Cancer Invest 2009; 27: 264-272.
17. Kuzmin I, Gillespie JW, Protopopov A, Geil L, Dreijerink K et al. The RASSF1A tumor suppressor gene is inactivated in prostate tumors and suppresses growth of prostate carcinoma cells. Cancer Res 2002; 62: 3498-3502. (Pubitemid 34651398)
18. Wilson AS, Power BE, Molloy PL. DNA hypomethylation and human diseases. Biochim Biophys Acta 2007; 1775: 138-162. (Pubitemid 44881198)
19. Ehrlich M. Cancer-linked DNA hypomethylation and its relationship to hypermethylation. Curr Top Microbiol Immunol 2006; 310: 251-274. (Pubitemid 47400293)
20. de Smet C, Loriot A. DNA hypomethylation in cancer: Epigenetic scars of a neoplastic journey. Epigenetics 2010; 5: 206-213.
21. Bracken AP, Helin K. Polycomb group proteins: Navigators of lineage pathways led astray in cancer. Nat Rev Cancer 2009; 9: 773-784.
22. Chase A, Cross NC. Aberrations of EZH2 in cancer. Clin Cancer Res 2011; 17: 2613-2618.
23. Cooper CS, Foster CS. Concepts of epigenetics in prostate cancer development. Br J Cancer 2009; 100: 240-245.
24. Yu J, Yu J, Rhodes DR, Tomlins SA, Cao X et al. A polycomb repression signature in metastatic prostate cancer predicts cancer outcome. Cancer Res 2007; 67: 10657-63. (Pubitemid 350145890)
25. Varambally S, Dhanasekaran SM, Zhou M, Barrette TR, Kumar-Sinha C et al. The polycomb group protein EZH2 is involved in progression of prostate cancer. Nature 2002; 419: 624-629.
26. Bracken AP, Pasini D, Capra M, Prosperini E, Colli E et al. EZH2 is downstream of the pRB-E2F pathway, essential for proliferation and amplified in cancer. EMBO J 2003; 22: 5323-5335. (Pubitemid 37279943)
27. Varambally S, Cao Q, Mani RS, Shankar S, Wang X et al. Genomic loss of microRNA-101 leads to overexpression of histone methyltransferase EZH2 in cancer. Science 2008; 322: 1695-1699.
28. Kunderfranco P, Mello-Grand M, Cangemi R, Pellini S, Mensah A et al. ETS transcription factors control transcription of EZH2 and epigenetic silencing of the tumor suppressor gene Nkx3.1 in prostate cancer. PLoS ONE 2010; 5: E10547.
29. Laitinen S, Martikainen PM, Tolonen T, Isola J, Tammela TL et al. EZH2, Ki-67 and MCM7 are prognostic markers in prostatectomy treated patients. Int J Cancer 2008; 122: 595-602. (Pubitemid 350308951)
30. Yu J, Rhodes DR, Tomlins SA, Cao X, Chen G et al. A polycomb repression signature in metastatic prostate cancer predicts cancer outcome. Cancer Res 2007; 67: 10657-63. (Pubitemid 350145890)
31. Hoffmann MJ, Engers R, Florl AR, Otte AP, Muller M et al. Expression changes in EZH2, but not in BMI-1, SIRT1, DNMT1 or DNMT3B are associated with DNA methylation changes in prostate cancer. Cancer Biol Ther 2007; 6: 1403-1412. (Pubitemid 351590350)
32. Cloos PA, Christensen J, Agger K, Maiolica A, Rappsilber J et al. The putative oncogene GASC1 demethylates tri- and dimethylated lysine 9 on histone H3. Nature 2006; 442: 307-311. (Pubitemid 44114906)
33. Kahl P, Gullotti L, Heukamp LC, Wolf S, Friedrichs N et al. Androgen receptor coactivators lysine-specific histone demethylase 1 and four and a half LIM domain protein 2 predict risk of prostate cancer recurrence. Cancer Res 2006; 66: 11341-7. (Pubitemid 46009965)
34. Wissmann M, Yin N, Muller JM, Greschik H, FodorBDet al. Cooperative demethylation by JMJD2C and LSD1 promotes androgen receptor-dependent gene expression. Nat Cell Biol 2007; 9: 347-353.
35. Metzger E, Wissmann M, Schule R. Histone demethylation and androgen-dependent transcription. Curr Opin Genet Dev 2006; 16: 513-517. (Pubitemid 44345210)
36. Xiang Y, Zhu Z, Han G, Ye X, Xu B et al. JARID1B is a histone H3 lysine 4 demethylase up-regulated in prostate cancer. Proc Natl Acad Sci USA 2007; 104: 19226-31.
37. Mabjeesh NJ, Willard MT, Frederickson CE, Zhong H, Simons JW. Androgens stimulate hypoxia-inducible factor 1 activation via autocrine loop of tyrosine kinase receptor/phosphatidylinositol 39-kinase/protein kinase B in prostate cancer cells. Clin Cancer Res 2003; 9: 2416-2425. (Pubitemid 36842080)
38. Morison IM, Ramsay JP, Spencer HG. A census of mammalian imprinting. Trends Genet 2005; 21: 457-465. (Pubitemid 40981795)
39. Henckel A, Nakabayashi K, Sanz LA, Feil R, Hata K et al. Histone methylation is mechanistically linked to DNA methylation at imprinting control regions in mammals. Hum Mol Genet 2009; 18: 3375-3383.
40. Regha K, Sloane MA, Huang R, Pauler FM, Warczok KE et al. Active and repressive chromatin are interspersed without spreading in an imprinted gene cluster in the mammalian genome. Mol Cell 2007; 27: 353-366. (Pubitemid 47161134)
41. McEwen KR, Ferguson-Smith AC. Distinguishing epigenetic marks of developmental and imprinting regulation. Epigenetics Chromatin 2010; 3: 2.
42. Zhao Z, Tavoosidana G, Sjolinder M, Gondor A, Mariano P et al. Circular chromosome conformation capture (4C) uncovers extensive networks of epigenetically regulated intra- and interchromosomal interactions. Nat Genet 2006; 38: 1341-1347. (Pubitemid 44646299)
43. Singh P, Wu X, Lee DH, Li AX, Rauch TA et al. Chromosome-wide analysis of parental allele-specific chromatin and DNA methylation. Mol Cell Biol 2011; 31: 1757-1770.
44. Delaval K, Govin J, Cerqueira F, Rousseaux S, Khochbin S et al. Differential histone modifications mark mouse imprinting control regions during spermatogenesis. EMBO J 2007; 26: 720-729.
45. Kacem S, Feil R. Chromatin mechanisms in genomic imprinting. Mamm Genome 2009; 20: 544-556.
46. Pauler FM, Koerner MV, Barlow DP. Silencing by imprinted noncoding RNAs: Is transcription the answer? Trends Genet 2007; 23: 284-292. (Pubitemid 46783843)
47. Peters J, Robson JE. Imprinted noncoding RNAs. Mamm Genome 2008; 19: 493-502.
48. Chaumeil J, Le Baccon P, Wutz A, Heard E. A novel role for Xist RNAin the formation of a repressive nuclear compartment into which genes are recruited when silenced. Genes Dev 2006; 20: 2223-2237.
49. Wu HA, Bernstein E. Partners in imprinting: Noncoding RNA and polycomb group proteins. Dev Cell 2008; 15: 637-638.
50. Reik W, Murrell A, Lewis A, Mitsuya K, Umlauf D et al. Chromosome loops, insulators, and histone methylation: New insights into regulation of imprinting in clusters. Cold Spring Harb Symp Quant Biol 2004; 69: 29-37. (Pubitemid 41056535)
51. Schoenfelder S, Clay I, Fraser P. The transcriptional interactome: gene expression in 3D. Curr Opin Genet Dev 2010; 20: 127-133.
52. Jeon Y, Lee JT. YY1 tethers Xist RNA to the inactive X nucleation center. Cell 2011; 146: 119-133.
53. Zhao J, Sun BK, Erwin JA, Song JJ, Lee JT. Polycomb proteins targeted by a short repeat RNA to the mouse X chromosome. Science 2008; 322: 750-756.
54. Angiolini E, Fowden A, Coan P, Sandovici I, Smith P et al. Regulation of placental efficiency for nutrient transport by imprinted genes. Placenta 2006; 27 (Suppl A): S98-102.
55. Moore T, Haig D. Genomic imprinting in mammalian development: A parental tug-ofwar. Trends Genet 1991; 7: 45-49. (Pubitemid 121001901)
56. Charalambous M, da Rocha ST, Ferguson-Smith AC. Genomic imprinting, growth control and the allocation of nutritional resources: Consequences for postnatal life. Curr Opin Endocrinol Diabetes Obes 2007; 14: 3-12. (Pubitemid 46375381)
57. Mann JR , Gadi I, Harbison ML, Abbondanzo SJ, Stewart CL. Androgenetic mouse embryonic stem cells are pluripotent and cause skeletal defects in chimeras: Implications for genetic imprinting. Cell 1990; 62: 251-260.
58. Wilkinson LS, Davies W, Isles AR. Genomic imprinting effects on brain development and function. Nat Rev Neurosci 2007; 8: 832-843. (Pubitemid 350006217)
59. Gabory A, Ripoche MA, Le Digarcher A, Watrin F, Ziyyat A et al. H19 acts as a trans regulator of the imprinted gene network controlling growth in mice. Development 2009; 136: 3413-3421.
60. Varrault A, Gueydan C, Delalbre A, Bellmann A, Houssami S et al. Zac1 regulates an imprinted gene network critically involved in the control of embryonic growth. Dev Cell 2006; 11: 711-722. (Pubitemid 44752557)
61. Berg JS, Lin KK, Sonnet C, Boles NC, WeksbergDC et al. Imprinted genes that regulate early Mammalian growth are coexpressed in somatic stem cells. PLoS ONE 2011; 6: E26410.
62. Eggermann T. Epigenetic regulation of growth: Lessons from Silver-Russell syndrome. Endocr Dev 2009; 14: 10-19.
63. Delaval K, Wagschal A, Feil R. Epigenetic deregulation of imprinting in congenital diseases of aberrant growth. Bioessays 2006; 28: 453-459. (Pubitemid 43668060)
64. Diaz-Meyer N, Yang Y, Sait SN, Maher ER, Higgins MJ. Alternative mechanisms associated with silencing of CDKN1C in Beckwith-Wiedemann syndrome. J Med Genet 2005; 42: 648-655. (Pubitemid 41129037)
65. Bliek J, Verde G, Callaway J, Maas SM, de Crescenzo A et al. Hypomethylation at multiple maternally methylated imprinted regions including PLAGL1 and GNAS loci in Beckwith-Wiedemann syndrome. Eur J Hum Genet 2009; 17: 611-619.
66. Hubertus J, Lacher M, Rottenkolber M, Muller-Hocker J, Berger M et al. Altered expression of imprinted genes in Wilms tumors. Oncol Rep 2011; 25: 817-823.
67. Suzuki S, Fujisawa D, Hashimoto K, Asano T, Maimaiti M et al. Partial paternal uniparental disomy of chromosome 6 in monozygotic twins with transient neonatal diabetes mellitus and macroglossia. Clin Genet 2010; 78: 580-584.
68. Temple IK, Shield JP. Transient neonatal diabetes, a disorder of imprinting. J Med Genet 2002; 39: 872-875. (Pubitemid 36009147)
69. Boissonnas CC, Abdalaoui HE, Haelewyn V, Fauque P, Dupont JM et al. Specific epigenetic alterations of IGF2-H19 locus in spermatozoa from infertile men. Eur J Hum Genet 2010; 18: 73-80.
70. Hammoud SS, Purwar J, Pflueger C, Cairns BR, Carrell DT. Alterations in sperm DNA methylation patterns at imprinted loci in two classes of infertility. Fertil Steril 2010; 94: 1728-1733.
71. Marques CJ, Costa P, Vaz B, Carvalho F, Fernandes S et al. Abnormal methylation of imprinted genes in human sperm is associated with oligozoospermia. MolHumReprod 2008; 14: 67-74.
72. Kobayashi H, Sato A, Otsu E, Hiura H, Tomatsu C et al. Aberrant DNA methylation of imprinted loci in sperm from oligospermic patients.HumMol Genet 2007; 16: 2542-2551.
73. Filipponi D, Feil R. Perturbation of genomic imprinting in oligozoospermia. Epigenetics 2009; 4: 27-30.
74. Rajender S, Avery K, Agarwal A. Epigenetics, spermatogenesis and male infertility. Mutat Res 2011; 727: 62-71.
75. Hammoud SS, Nix DA, Hammoud AO, Gibson M, Cairns BR et al. Genome-wide analysis identifies changes in histone retention and epigenetic modifications at developmental and imprinted gene loci in the sperm of infertile men. Hum Reprod 2011; 26: 2558-2569.
76. Hammoud SS, Nix DA, Zhang H, Purwar J, Carrell DT et al. Distinctive chromatin in human sperm packages genes for embryo development. Nature 2009; 460: 473-478.
77. Bernstein BE, Mikkelsen TS, Xie X, Kamal M, Huebert DJ et al. A bivalent chromatin structure marks key developmental genes in embryonic stem cells. Cell 2006; 125: 315-326.
78. Ooi SK, Qiu C, Bernstein E, Li K, Jia D et al. DNMT3L connects unmethylated lysine 4 of histone H3 to de novo methylation of DNA. Nature 2007; 448: 714-717. (Pubitemid 47236857)
79. Schlesinger Y, Straussman R, Keshet I, Farkash S, HechtMet al. Polycomb-mediated methylation on Lys27 of histone H3 pre-marks genes for de novo methylation in cancer. Nat Genet 2007; 39: 232-236. (Pubitemid 46184355)
80. Fu VX, Dobosy JR, Desotelle JA, Almassi N, Ewald JA et al. Aging and cancer-related loss of insulin-like growth factor 2 imprinting in the mouse and human prostate. Cancer Res 2008; 68: 6797-6802.
81. Jelinic P, Shaw P. Loss of imprinting and cancer. J Pathol 2007; 211: 261-268. (Pubitemid 46172701)
82. Bhusari S, Yang B, Kueck J, Huang W, Jarrard DF. Insulin-like growth factor-2 (IGF2) loss of imprinting marks a field defect within human prostates containing cancer. Prostate 2011; 71: 1621-1630.
83. Cruz-Correa M, Cui H, Giardiello FM, Powe NR, Hylind L et al. Loss of imprinting of insulin growth factor II gene: A potential heritable biomarker for colon neoplasia predisposition. Gastroenterology 2004; 126: 964-970. (Pubitemid 38451167)
84. Chao W, D'Amore PA. IGF2: Epigenetic regulation and role in development and disease. Cytokine Growth Factor Rev 2008; 19: 111-120. (Pubitemid 351382280)
85. Sandhu KS, Shi C, Sjolinder M, Zhao Z, Gondor A et al. Nonallelic transvection of multiple imprinted loci is organized by the H19 imprinting control region during germline development. Genes Dev 2009; 23: 2598-2603.
86. Murrell A, Heeson S, Reik W. Interaction between differentially methylated regions partitions the imprinted genes Igf2 and H19 into parent-specific chromatin loops. Nat Genet 2004; 36: 889-893. (Pubitemid 39014109)
87. Vu TH, Nguyen AH, Hoffman AR. Loss of IGF2 imprinting is associated with abrogation of long-range intrachromosomal interactions in human cancer cells. Hum Mol Genet 2010; 19: 901-919.
88. Pant V, Kurukuti S, Pugacheva E, Shamsuddin S, Mariano P et al. Mutation of a single CTCF target site within the H19 imprinting control region leads to loss of Igf2 imprinting and complex patterns of de novo methylation upon maternal inheritance. Mol Cell Biol 2004; 24: 3497-3504. (Pubitemid 38452088)
89. Kawada M, Inoue H, Masuda T, Ikeda D. Insulin-like growth factor I secreted from prostate stromal cells mediates tumor-stromal cell interactions of prostate cancer. Cancer Res 2006; 66: 4419-4425.
90. Cardillo MR, Monti S, Di Silverio F, Gentile V, Sciarra F et al. Insulin-like growth factor (IGF)-I, IGF-II and IGF type I receptor (IGFR-I) expression in prostatic cancer. Anticancer Res 2003; 23: 3825-3835. (Pubitemid 37479239)
91. Tennant MK, Thrasher JB, Twomey PA, Drivdahl RH, Birnbaum RS et al. Protein and messenger ribonucleic acid (mRNA) for the type 1 insulin-like growth factor (IGF) receptor is decreased and IGF-II mRNA is increased in human prostate carcinoma compared to benign prostate epithelium. J Clin Endocrinol Metab 1996; 81: 3774-3782. (Pubitemid 26339953)
92. Turney BW, Turner GD, Brewster SF, Macaulay VM. Serial analysis of resected prostate cancer suggests up-regulation of type 1 IGF receptor with disease progression. BJU Int 2011; 107: 1488-1499.
93. Le H, Arnold JT, McFann KK, Blackman MR. DHT and testosterone, but not DHEA or E2, differentially modulate IGF-I, IGFBP-2, and IGFBP-3 in human prostatic stromal cells. Am J Physiol Endocrinol Metab 2006; 290: E952-60.
94. Liu X, Allen JD, Arnold JT, Blackman MR. Lycopene inhibits IGF-I signal transduction and growth in normal prostate epithelial cells by decreasing DHT-modulated IGF-I production in co-cultured reactive stromal cells. Carcinogenesis 2008; 29: 816-823. (Pubitemid 351494170)
95. Liu X, Choi RY, Jawad SM, Arnold JT. Androgen-induced PSA expression requires not only activation of AR but also endogenous IGF-I or IGF-I/PI3K/Akt signaling in human prostate cancer epithelial cells. Prostate 2010; 71: 766-777.
96. Taylor BS, Schultz N, Hieronymus H, Gopalan A, Xiao Y et al. Integrative genomic profiling of human prostate cancer. Cancer Cell 2010; 18: 11-22.
97. El Sheikh SS, Romanska HM, Abel P, Domin J et al. Predictive value of PTEN and AR coexpression of sustained responsiveness to hormonal therapy in prostate cancer-A pilot study. Neoplasia 2008; 10: 949-953.
98. Agoulnik IU, Hodgson MC, Bowden WA, Ittmann MM. INPP4B: The new kid on the PI3K block. Oncotarget 2011; 2: 321-328.
99. Hodgson MC, Shao LJ, Frolov A, Li R, Peterson LE et al. Decreased expression and androgen regulation of the tumor suppressor gene INPP4B in prostate cancer. Cancer Res 2011; 71: 572-582.
100. Carver BS, Chapinski C, Wongvipat J, Hieronymus H, Chen Y et al. Reciprocal feedback regulation of PI3K and androgen receptor signaling in PTEN-deficient prostate cancer. Cancer Cell 2011; 19: 575-586.
101. Sarker D, Reid AH, Yap TA, de Bono JS. Targeting the PI3K/AKT pathway for the treatment of prostate cancer. Clin Cancer Res 2009; 15: 4799-4805.
102. PlymateSR, Tennant MK, Culp SH, Woodke L, MarcelliMet al. Androgen receptor (AR expression in AR-negative prostate cancer cells results in differential effects of DHT and IGF-I on proliferation and AR activity between localized and metastatic tumors. Prostate 2004; 61: 276-290. (Pubitemid 39350451)
103. WuJD, Haugk K, Woodke L, Nelson P, Coleman I et al. Interaction of IGF signaling and the androgen receptor in prostate cancer progression. J Cell Biochem 2006; 99: 392-401. (Pubitemid 44435557)
104. Gregory CW, He B, Johnson RT, Ford OH, Mohler JL et al. A mechanism for androgen receptor-mediated prostate cancer recurrence after androgen deprivation therapy. Cancer Res 2001; 61: 4315-4319. (Pubitemid 32685750)
105. Kupfer SR, Wilson EM, French FS. Androgen and glucocorticoid receptors interact with insulin degrading enzyme. J Biol Chem 1994; 269: 20622-8. (Pubitemid 24260473)
106. Shen MM, Abate-Shen C. Molecular genetics of prostate cancer: New prospects for old challenges. Genes Dev 2010; 24: 1967-2000.
107. Fan W, Yanase T, Morinaga H, Okabe T, Nomura M et al. Insulin-like growth factor 1/insulin signaling activates androgen signaling through direct interactions of Foxo1 with androgen receptor. J Biol Chem 2007; 282: 7329-7338. (Pubitemid 47093686)
108. Feldman BJ, Feldman D. The development of androgen-independent prostate cancer. Nat Rev Cancer 2001; 1: 34-45. (Pubitemid 33741879)
109. McKenzie S, Kyprianou N. Apoptosis evasion: The role of survival pathways in prostate cancer progression and therapeutic resistance. J Cell Biochem 2006; 97: 18-32. (Pubitemid 43050177)
110. Ozkan EE. Plasma and tissue insulin-like growth factor-I receptor (IGF-IR) as a prognostic marker for prostate cancer and anti-IGF-IR agents as novel therapeutic strategy for refractory cases: A review. Mol Cell Endocrinol 2011; 344: 1-24.
111. Jarrard DF, Bussemakers MJ, Bova GS, Isaacs WB. Regional loss of imprinting of the insulin-like growth factor II gene occurs in human prostate tissues. Clin Cancer Res 1995; 1: 1471-1478. (Pubitemid 26028082)
112. Murrell A, Ito Y, Verde G, Huddleston J, WoodfineKet al. Distinct methylation changes at the IGF2-H19 locus in congenital growth disorders and cancer. PLoS ONE2008; 3: E1849.
113. Cui H, Cruz-Correa M, Giardiello FM, Hutcheon DF, Kafonek DR et al. Loss of IGF2 imprinting: A potential marker of colorectal cancer risk. Science 2003; 299: 1753-1755. (Pubitemid 36337205)
114. Issa JP, Vertino PM, Boehm CD, Newsham IF, Baylin SB. Switch from monoallelic to biallelic human IGF2 promoter methylation during aging and carcinogenesis. Proc Natl Acad Sci USA 1996; 93: 11757-62. (Pubitemid 26347196)
115. Paradowska A, Fenic I, Konrad L, Sturm K, Wagenlehner F et al. Aberrant epigenetic modifications in the CTCF binding domain of the IGF2/H19 gene in prostate cancer compared with benign prostate hyperplasia. Int J Oncol 2009; 35: 87-96.
116. Fu VX, Schwarze SR, Kenowski ML, Leblanc S, Svaren J et al. A loss of insulin-like growth factor-2 imprinting is modulated by CCCTC-binding factor down-regulation at senescence in human epithelial cells. J Biol Chem 2004; 279: 52218-26. (Pubitemid 39656596)
117. Matouk IJ, Mezan S, Mizrahi A, Ohana P, Abu-Lail R et al. The oncofetal H19 RNA connection: Hypoxia, p53 and cancer. Biochim Biophys Acta 2010; 1803: 443-451.
118. Yang J, Mani SA, Donaher JL, Ramaswamy S, Itzykson RA et al. Twist, a master regulator of morphogenesis, plays an essential role in tumor metastasis. Cell 2004; 117: 927-939. (Pubitemid 38798858)
119. Matouk IJ, DeGroot N, Mezan S, Ayesh S, Abu-lail R et al. The H19 non-coding RNA is essential for human tumor growth. PLoS ONE 2007; 2: E845.
120. Bliek J, Terhal P, van Den Bogaard MJ, Maas S, Hamel B et al. Hypomethylation of the H19 gene causes not only Silver-Russell syndrome (SRS) but also isolated asymmetry or an SRS-like phenotype. Am J Hum Genet 2006; 78: 604-614.
121. Bliek J, Maas SM, Ruijter JM, Hennekam RC, AldersMet al. Increased tumour risk for BWS patients correlates with aberrant H19 and not KCNQ1OT1 methylation: Occurrence of KCNQ1OT1 hypomethylation in familial cases of BWS. Hum Mol Genet 2001; 10: 467-76. (Pubitemid 32181669)
122. Berteaux N, Lottin S, Adriaenssens E, van Coppenolle F, Leroy X et al. Hormonal regulation of H19 gene expression in prostate epithelial cells. J Endocrinol 2004; 183: 69-78. (Pubitemid 40124644)
123. Cui H. Loss of imprinting of IGF2 as an epigenetic marker for the risk of human cancer. Dis Markers 2007; 23: 105-112. (Pubitemid 46333644)
124. Gray TA, Saitoh S, Nicholls RD. An imprinted, mammalian bicistronic transcript encodes two independent proteins. Proc Natl Acad Sci USA 1999; 96: 5616-5621. (Pubitemid 29234667)
125. Nicholls RD. The impact of genomic imprinting for neurobehavioral and developmental disorders. J Clin Invest 2000; 105: 413-418. (Pubitemid 30127240)
126. Kamiya M, Judson H, Okazaki Y, Kusakabe M, Muramatsu M et al. The cell cycle control gene ZAC/PLAGL1 is imprinted-A strong candidate gene for transient neonatal diabetes. Hum Mol Genet 2000; 9: 453-460. (Pubitemid 30098740)
127. Valente T, Junyent F, Auladell C. Zac1 is expressed in progenitor/stem cells of the neuroectoderm and mesoderm during embryogenesis: Differential phenotype of the Zac1-expressing cells during development. Dev Dyn 2005; 233: 667-679. (Pubitemid 40734067)
128. Bilanges B, Varrault A, Mazumdar A, Pantaloni C, Hoffmann A et al. Alternative splicing of the imprinted candidate tumor suppressor gene ZAC regulates its antiproliferative and DNA binding activities. Oncogene 2001; 20: 1246-1253. (Pubitemid 32226251)
129. Hoffmann A, Ciani E, Boeckardt J, Holsboer F, Journot L et al. Transcriptional activities of the zinc finger protein Zac are differentially controlled by DNA binding. Mol Cell Biol 2003; 23: 988-1003. (Pubitemid 36133516)
130. Barz T, Hoffmann A, Panhuysen M, Spengler D. Peroxisome proliferator-Activated receptor gamma is a Zac target gene mediating Zac antiproliferation. Cancer Res 2006; 66: 11975-82. (Pubitemid 46094211)
131. Spengler D, Villalba M, Hoffmann A, Pantaloni C, Houssami S et al. Regulation of apoptosis and cell cycle arrest by Zac1, a novel zinc finger protein expressed in the pituitary gland and the brain. EMBO J 1997; 16: 2814-2825. (Pubitemid 27226218)
132. Hoffmann A, Spengler D. A new coactivator function for Zac1's C2H2 zinc finger DNAbinding domain in selectively controlling PCAF activity. Mol Cell Biol 2008; 28: 6078-6093.
133. Huang SM, Stallcup MR. Mouse Zac1, a transcriptional coactivator and repressor for nuclear receptors. Mol Cell Biol 2000; 20: 1855-1867. (Pubitemid 30100202)
134. Huang SM, Schonthal AH, Stallcup MR. Enhancement of p53-dependent gene activation by the transcriptional coactivator Zac1. Oncogene 2001; 20: 2134-2143. (Pubitemid 32424007)
135. Rozenfeld-Granot G, Krishnamurthy J, Kannan K, Toren A, AmariglioNet al. A positive feedback mechanism in the transcriptional activation of Apaf-1 by p53 and the coactivator Zac-1. Oncogene 2002; 21: 1469-1476. (Pubitemid 34226133)
136. Liu PY, Chan JY, Lin HC, Wang SL, Liu ST et al. Modulation of the cyclin-dependent kinase inhibitor p21(WAF1/Cip1) gene by Zac1 through the antagonistic regulators p53 and histone deacetylase 1 in HeLa Cells. Mol Cancer Res 2008; 6: 1204-1214.
137. Abdollahi A, Godwin AK, Miller PD, Getts LA, Schultz DC et al. Identification of a gene containing zinc-finger motifs based on lost expression in malignantly transformed rat ovarian surface epithelial cells. Cancer Res 1997; 57: 2029-2034. (Pubitemid 27209737)
138. Abdollahi A, Roberts D, Godwin AK, Schultz DC, Sonoda G et al. Identification of a zinc-finger gene at 6q25: A chromosomal region implicated in development of many solid tumors. Oncogene 1997; 14: 1973-1979. (Pubitemid 27217810)
139. Basyuk E, Coulon V, Le Digarcher A, Coisy-Quivy M, Moles JP et al. The candidate tumor suppressor gene ZAC is involved in keratinocyte differentiation and its expression is lost in basal cell carcinomas. Mol Cancer Res 2005; 3: 483-492. (Pubitemid 41377638)
140. Cvetkovic D, Pisarcik D, Lee C, Hamilton TC, Abdollahi A. Altered expression and loss of heterozygosity of the LOT1 gene in ovarian cancer. Gynecol Oncol 2004; 95: 449-455. (Pubitemid 39592503)
141. Pagotto U, Arzberger T, Theodoropoulou M, Grubler Y, Pantaloni C et al. The expression of the antiproliferative gene ZAC is lost or highly reduced in nonfunctioning pituitary adenomas. Cancer Res 2000; 60: 6794-6799. (Pubitemid 32059140)
142. Koy S, Hauses M, Appelt H, Friedrich K, SchackertHK et al. Loss of expression of ZAC/LOT1 in squamous cell carcinomas of head and neck. Head Neck 2004; 26: 338-344. (Pubitemid 38436673)
143. Varrault A, Ciani E, Apiou F, Bilanges B, Hoffmann A et al. hZAC encodes a zinc finger protein with antiproliferative properties and maps to a chromosomal region frequently lost in cancer. Proc Natl Acad Sci USA 1998; 95: 8835-8840.
144. Monk D, Wagschal A, Arnaud P, Muller PS, Parker-Katiraee L et al. Comparative analysis of human chromosome 7q21 and mouse proximal chromosome 6 reveals a placental-specific imprinted gene, TFPI2/Tfpi2, which requires EHMT2 and EED for allelic-silencing. Genome Res 2008; 18: 1270-1281.
145. Suzuki S, Ono R, Narita T, Pask AJ, Shaw G et al. Retrotransposon silencing by DNA methylation can drive mammalian genomic imprinting. PLoS Genet. 2007; 3: E55.
146. Lux H, Flammann H, Hafner M, Lux A. Genetic and molecular analyses of PEG10 reveal new aspects of genomic organization, transcription and translation. PLoS ONE 2010; 5: E8686.
147. Glockner SC, Dhir M, Yi JM, McGarvey KE, van Neste L et al. Methylation of TFPI2 in stool DNA: A potential novel biomarker for the detection of colorectal cancer. Cancer Res 2009; 69: 4691-4699.
148. Guo H, Lin Y, Zhang H, Liu J, Zhang N et al. Tissue factor pathway inhibitor-2 was repressed by CpG hypermethylation through inhibition of KLF6 binding in highly invasive breast cancer cells. BMC Mol Biol 2007; 8: 110.
149. Konduri SD, Tasiou A, Chandrasekar N, Rao JS. Overexpression of tissue factor pathway inhibitor-2 (TFPI-2), decreases the invasiveness of prostate cancer cells in vitro. Int J Oncol 2001; 18: 127-131.
150. Rao CN, Segawa T, Navari JR, Xu L, Srivastava S et al. Methylation of TFPI-2 gene is not the sole cause of its silencing. Int J Oncol 2003; 22: 843-848.
151. Ribarska T, Ingenwerth M, Goering W, Engers R, Schulz WA. Epigenetic inactivation of the placentally imprinted tumor suppressor gene TFPI2 in prostate carcinoma. Cancer Genomics Proteomics 2010; 7: 51-60.
152. Kobayashi M, Ishida H, Shindo T, Niwa S, Kino M et al. Molecular analysis of multifocal prostate cancer by comparative genomic hybridization. Prostate 2008; 68: 1715-1724.
153. Kainz B, Shehata M, Bilban M, Kienle D, Heintel D et al. Overexpression of the paternally expressed gene 10 (PEG10) from the imprinted locus on chromosome 7q21 in high-risk B-cell chronic lymphocytic leukemia. Int J Cancer 2007; 121: 1984-1993. (Pubitemid 47463161)
154. Okabe H, Satoh S, Furukawa Y, Kato T, Hasegawa S et al. Involvement of PEG10 in human hepatocellular carcinogenesis through interaction with SIAH1. Cancer Res 2003; 63: 3043-3048. (Pubitemid 36735848)
155. Tsou AP, Chuang YC, Su JY, Yang CW, Liao YL et al. Overexpression of a novel imprinted gene, PEG10, in human hepatocellular carcinoma and in regenerating mouse livers. J Biomed Sci 2003; 10: 625-635.
156. Dong H, Zhang H, Liang J, Yan H, Chen Y et al. Digital karyotyping reveals probable target genes at 7q21.3 locus in hepatocellular carcinoma.BMCMed Genomics 2011; 4: 60.
157. Tsuji K, Yasui K, Gen Y, Endo M, Dohi O et al. PEG10 is a probable target for the amplification at 7q21 detected in hepatocellular carcinoma. Cancer Genet Cytogenet 2010; 198: 118-125.
158. Jie X, Lang C, Jian Q, Chaoqun L, Dehua Y et al. Androgen activates PEG10 to promote carcinogenesis in hepatic cancer cells. Oncogene 2007; 26: 5741-5751. (Pubitemid 47312814)
159. Li CM, Margolin AA, Salas M, Memeo L, MansukhaniMet al. PEG10 is a c-MYC target gene in cancer cells. Cancer Res 2006; 66: 665-672. (Pubitemid 43165928)
160. Lux A, Beil C, Majety M, Barron S, Gallione CJ et al. Human retroviral gag- and gag-pollike proteins interact with the transforming growth factor-beta receptor activin receptor-like kinase 1. J Biol Chem 2005; 280: 8482-8493. (Pubitemid 40349753)
161. Bonnemann CG, McNally EM, Kunkel LM. Beyond dystrophin: Current progress in the muscular dystrophies. Curr Opin Pediatr 1996; 8: 569-582. (Pubitemid 27026787)
162. Ritz K, van Schaik BD, Jakobs ME, van Kampen AH, Aronica E et al. SGCE isoform characterization and expression in human brain: Implications for myoclonus-dystonia pathogenesis? Eur J Hum Genet 2011; 19: 438-444.
163. Ortega P, Moran A, Fernandez-Marcelo T, de Juan C, Frias C et al. MMP-7 and SGCE as distinctive molecular factors in sporadic colorectal cancers from the mutator phenotype pathway. Int J Oncol 2010; 36: 1209-1215.
164. Oliver CJ, Terry-Lorenzo RT, Elliott E, Bloomer WA, Li S et al. Targeting protein phosphatase 1 (PP1) to the actin cytoskeleton: The neurabin I/PP1 complex regulates cell morphology. Mol Cell Biol 2002; 22: 4690-4701. (Pubitemid 34620405)
165. Duhadaway J, Rowe F, Elliott K, Mao NC, Prendergast GC. Bau, a splice form of Neurabin-I that interacts with the tumor suppressor Bin1, inhibits malignant cell transformation. Cell Adhes Commun 1999; 7: 99-110.
166. Choi JD, Underkoffler LA, Wood AJ, Collins JN, Williams PT et al. A novel variant of Inpp5f is imprinted in brain, and its expression is correlated with differential methylation of an internal CpG island. Mol Cell Biol 2005; 25: 5514-5522. (Pubitemid 40853586)
167. Zhu W, Trivedi CM, Zhou D, Yuan L, Lu MM et al. Inpp5f is a polyphosphoinositide phosphatase that regulates cardiac hypertrophic responsiveness. Circ Res 2009; 105: 1240-1247.
168. Pateras IS, Apostolopoulou K, Niforou K, Kotsinas A, Gorgoulis VG. p57KIP2: "Kip"ing the cell under control. Mol Cancer Res 2009; 7: 1902-1919.
169. Andrews SC, Wood MD, Tunster SJ, Barton SC, Surani MA et al. Cdkn1c (p57Kip2) is the major regulator of embryonic growth within its imprinted domain on mouse distal chromosome 7. BMC Dev Biol 2007; 7: 53.
170. MaY, Chen L, Wright GM, Pillai SR, Chellappan SP et al. CDKN1Cnegatively regulates RNA polymerase II C-Terminal domain phosphorylation in an E2F1-dependent manner. J Biol Chem 2010; 285: 9813-9822.
171. Kavanagh E, Joseph B. The hallmarks of CDKN1C (p57, KIP2) in cancer. Biochim Biophys Acta 2011; 1816: 50-56.
172. Schwarze SR, Shi Y, Fu VX, Watson PA, Jarrard DF. Role of cyclin-dependent kinase inhibitors in the growth arrest at senescence in human prostate epithelial and uroepithelial cells. Oncogene 2001; 20: 8184-8192. (Pubitemid 34038207)
173. Lodygin D, Epanchintsev A, Menssen A, Diebold J, Hermeking H. Functional epigenomics identifies genes frequently silenced in prostate cancer. Cancer Res 2005; 65: 4218-4227. (Pubitemid 40775660)
174. Hoffmann MJ, Florl AR, Seifert HH, Schulz WA. Multiple mechanisms downregulate CDKN1C in human bladder cancer. Int J Cancer 2005; 114: 406-413. (Pubitemid 40279961)
175. Yang X, Karuturi RK, Sun F, Aau M, YuKet al.CDKN1C(p57) is a direct target of EZH2 and suppressed by multiple epigenetic mechanisms in breast cancer cells. PLoS ONE 2009; 4: E5011.
176. Algar EM, Muscat A, Dagar V, Rickert C, Chow CW et al. Imprinted CDKN1C is a tumor suppressor in rhabdoid tumor and activated by restoration of SMARCB1 and histone deacetylase inhibitors. PLoS ONE 2009; 4: E4482.
177. Schwienbacher C, Gramantieri L, Scelfo R, Veronese A, Calin GA et al. Gain of imprinting at chromosome 11p15: A pathogenetic mechanism identified in human hepatocarcinomas. Proc Natl Acad Sci USA 2000; 97: 5445-5449. (Pubitemid 30313738)
178. Lin SP, Youngson N, Takada S, Seitz H, Reik W et al. Asymmetric regulation of imprinting on the maternal and paternal chromosomes at the Dlk1-Gtl2 imprinted cluster on mouse chromosome 12. Nat Genet 2003; 35: 97-102. (Pubitemid 37048602)
179. Lujan E, Wernig M. An imprinted signature helps isolate ESC-equivalent iPSCs. Cell Res 2010; 20: 974-976.
180. Luk JM, Burchard J, Zhang C, Liu AM, Wong KF et al. DLK1-DIO3 genomic imprinted microrna cluster at 14q32.2 defines a stemlike subtype of hepatocellular carcinoma associated with poor survival. J Biol Chem 2011; 286: 30706-13.
181. Abdallah BM, Jensen CH, Gutierrez G, Leslie RG, Jensen TG et al. Regulation of human skeletal stem cells differentiation by Dlk1/Pref-1. J Bone Miner Res 2004; 19: 841-852. (Pubitemid 41094396)
182. Liu L, Luo GZ, Yang W, Zhao X, Zheng Q et al. Activation of the imprinted Dlk1-Dio3 region correlates with pluripotency levels of mouse stem cells. J Biol Chem 2010; 285: 19483-90.
183. Kagami M, O'Sullivan MJ, Green AJ, Watabe Y, Arisaka O et al. The IG-DMR and the MEG3-DMR at human chromosome 14q32.2: Hierarchical interaction and distinct functional properties as imprinting control centers. PLoS Genet 2010; 6: E1000992.
184. Zhou Y, Cheunsuchon P, Nakayama Y, Lawlor MW, Zhong Y et al. Activation of paternally expressed genes and perinatal death caused by deletion of the Gtl2 gene. Development 2010; 137: 2643-2652.
185. Irving MD, Buiting K, Kanber D, Donaghue C, Schulz R et al. Segmental paternal uniparental disomy (patUPD) of 14q32 with abnormal methylation elicits the characteristic features of complete patUPD14. Am J Med Genet A 2010; 152A: 1942-1950.
186. Kawakami T, Chano T, Minami K, Okabe H, Okada Y et al. Imprinted DLK1 is a putative tumor suppressor gene and inactivated by epimutation at the region upstream of GTL2 in human renal cell carcinoma. Hum Mol Genet 2006; 15: 821-830. (Pubitemid 43338225)
187. Benetatos L, Vartholomatos G, Hatzimichael E. MEG3 imprinted gene contribution in tumorigenesis. Int J Cancer 2011; 129: 773-779.
188. Bolos V, Grego-Bessa J, de la Pompa JL. Notch signaling in development and cancer. Endocr Rev 2007; 28: 339-363. (Pubitemid 46984831)
189. Wang XD, Shou J, Wong P, French DM, Gao WQ. Notch1-expressing cells are indispensable for prostatic branching morphogenesis during development and regrowth following castration and androgen replacement. J Biol Chem 2004; 279: 24733-44. (Pubitemid 38725341)
190. Baladron V, Ruiz-Hidalgo MJ, Nueda ML, Diaz-Guerra MJ, Garcia-Ramirez JJ et al. dlk acts as a negative regulator of Notch1 activation through interactions with specific EGF-like repeats. Exp Cell Res 2005; 303: 343-359. (Pubitemid 40126268)
191. Ceder JA, Jansson L, Helczynski L, Abrahamsson PA. Delta-like 1 (Dlk-1), a novel marker of prostate basal and candidate epithelial stem cells, is downregulated by notch signalling in intermediate/transit amplifying cells of the human prostate. Eur Urol 2008; 54: 1344-1353.
192. Belandia B, Parker MG. Nuclear receptor regulation gears up another Notch. Nucl Recept Signal 2006; 4: E001.
193. Koch U, Radtke F. Notch and cancer: A double-edged sword. Cell Mol Life Sci 2007; 64: 2746-2762. (Pubitemid 351152259)
194. Whelan JT, Kellogg A, Shewchuk BM, Hewan-Lowe K, Bertrand FE. Notch-1 signaling is lost in prostate adenocarcinoma and promotes PTEN gene expression. J Cell Biochem 2009; 107: 992-1001.
195. Santagata S, Demichelis F, Riva A, Varambally S, HoferMDet al. JAGGED1 expression is associated with prostate cancer metastasis and recurrence. Cancer Res 2004; 64: 6854-6857. (Pubitemid 39330990)
196. Christofori G. Metastatic colon cancer cells negotiate the intravasation Notch. Cancer Cell 2011; 19: 6-8.
197. Leong KG, Niessen K, Kulic I, Raouf A, Eaves C et al. Jagged1-mediated Notch activation induces epithelial-To-mesenchymal transition through Slug-induced repression of E-cadherin. J Exp Med 2007; 204: 2935-2948. (Pubitemid 350179562)
198. Villaronga MA, Lavery DN, Bevan CL, Llanos S, Belandia B. HEY1 Leu94Met gene polymorphism dramatically modifies its biological functions. Oncogene 2010; 29: 411-420.
199. Gutierrez A, Look AT.NOTCHand PI3K-AKT pathways intertwined. Cancer Cell 2007; 12: 411-413. (Pubitemid 350046412)
200. Kuwajima T, Nishimura I, Yoshikawa K. Necdin promotes GABAergic neuron differentiation in cooperation with Dlx homeodomain proteins. J Neurosci 2006; 26: 5383-5392. (Pubitemid 44318390)
201. Pagliardini S, Ren J, Wevrick R, Greer JJ. Developmental abnormalities of neuronal structure and function in prenatal mice lacking the Prader-Willi syndrome gene necdin. Am J Pathol 2005; 167: 175-191. (Pubitemid 40884780)
202. Zhu NL, Wang J, Tsukamoto H. The Necdin-Wnt pathway causes epigenetic peroxisome proliferator-Activated receptor gamma repression in hepatic stellate cells. J Biol Chem 2010; 285: 30463-71.
203. Taniura H, Taniguchi N, Hara M, Yoshikawa K. Necdin, a postmitotic neuron-specific growth suppressor, interacts with viral transforming proteins and cellular transcription factor E2F1. J Biol Chem 1998; 273: 720-728. (Pubitemid 28049158)
204. Kubota Y, Osawa M, Jakt LM, Yoshikawa K, Nishikawa S. Necdin restricts proliferation of hematopoietic stem cells during hematopoietic regeneration. Blood 2009; 114: 4383-4392.
205. Taniura H, Yoshikawa K. Necdin interacts with the ribonucleoprotein hnRNP U in the nuclear matrix. J Cell Biochem 2002; 84: 545-555.
206. Hasegawa K, Yoshikawa K. Necdin regulates p53 acetylation via Sirtuin1 to modulate DNA damage response in cortical neurons. J Neurosci 2008; 28: 8772-8784.
207. Chapman EJ, Knowles MA. Necdin: A multi functional protein with potential tumor suppressor role? Mol Carcinog 2009; 48: 975-981.
208. Kim JD, Kang K, Kim J. YY1's role in DNA methylation of Peg3 and Xist. Nucleic Acids Res 2009; 37: 5656-5664.
209. Chen MY, Liao WS, Lu Z, Bornmann WG, Hennessey V et al. Decitabine and suberoylanilide hydroxamic acid (SAHA) inhibit growth of ovarian cancer cell lines and xenografts while inducing expression of imprinted tumor suppressor genes, apoptosis, G2/M arrest, and autophagy. Cancer 2011; 117: 4424-4438.
210. Dowdy SC, Gostout BS, Shridhar V, Wu X, Smith DI et al. Biallelic methylation and silencing of paternally expressed gene 3 (PEG3) in gynecologic cancer cell lines. Gynecol Oncol 2005; 99: 126-134. (Pubitemid 41354593)
211. Feng W, Marquez RT, Lu Z, Liu J, Lu KHet al. Imprinted tumor suppressor genes ARHI and PEG3 are the most frequently down-regulated in human ovarian cancers by loss of heterozygosity and promoter methylation. Cancer 2008; 112: 1489-1502. (Pubitemid 351441161)
212. Maegawa S, Yoshioka H, Itaba N, Kubota N, Nishihara S et al. Epigenetic silencing of PEG3 gene expression in human glioma cell lines. Mol Carcinog 2001; 31: 1-9. (Pubitemid 32520662)
213. Otsuka S, Maegawa S, Takamura A, Kamitani H, Watanabe T et al. Aberrant promoter methylation and expression of the imprinted PEG3 gene in glioma. Proc Jpn Acad Ser B Phys Biol Sci 2009; 85: 157-165.
214. Maegawa S, Itaba N, Otsuka S, Kamitani H, Watanabe T et al. Coordinate downregulation of a novel imprinted transcript ITUP1 with PEG3 in glioma cell lines. DNA Res 2004; 11: 37-49. (Pubitemid 40036633)
215. Besson V, Smeriglio P, Wegener A, Relaix F, Nait Oumesmar B et al. PW1 gene/paternally expressed gene 3 (PW1/Peg3) identifies multiple adult stem and progenitor cell populations. Proc Natl Acad Sci USA 2011; 108: 11470-5.
216. Li L, Keverne EB, Aparicio SA, Ishino F, Barton SC et al. Regulation of maternal behavior and offspring growth by paternally expressed Peg3. Science 1999; 284: 330-333.
217. Johnson MD, Wu X, Aithmitti N, Morrison RS. Peg3/Pw1 is a mediator between p53 and Bax in DNA damage-induced neuronal death. J Biol Chem 2002; 277: 23000-7. (Pubitemid 34967286)
218. Relaix F, Wei X, Li W, Pan J, Lin Y et al. Pw1/Peg3 is a potential cell death mediator and cooperates with Siah1a in p53-mediated apoptosis. Proc Natl Acad Sci USA 2000; 97: 2105-2110. (Pubitemid 30134029)
219. Relaix F, Wei XJ, Wu X, Sassoon DA. Peg3/Pw1 is an imprinted gene involved in the TNF-NFkappaB signal transduction pathway. Nat Genet 1998; 18: 287-291. (Pubitemid 28117271)
220. Jiang X, Yu Y, Yang HW, Agar NY, Frado L et al. The imprinted gene PEG3 inhibits Wnt signaling and regulates glioma growth. J Biol Chem 2010; 285: 8472-8480.
221. Cronauer MV, Schulz WA, Ackermann R, Burchardt M. Effects of WNT/beta-catenin pathway activation on signaling through T-cell factor and androgen receptor in prostate cancer cell lines. Int J Oncol 2005; 26: 1033-1040.
222. Li H, Kim JH, Koh SS, Stallcup MR. Synergistic effects of coactivators GRIP1 and beta-catenin on gene activation: Cross-Talk between androgen receptor and Wnt signaling pathways. J Biol Chem 2004; 279: 4212-4220. (Pubitemid 38199008)
223. Song LN, Gelmann EP. Interaction of beta-catenin and TIF2/GRIP1 in transcriptional activation by the androgen receptor. J Biol Chem 2005; 280: 37853-67. (Pubitemid 41642397)
224. Song LN, Herrell R, Byers S, Shah S, Wilson EM et al. Beta-catenin binds to the activation function 2 region of the androgen receptor and modulates the effects of the N-Terminal domain and TIF2 on ligand-dependent transcription. Mol Cell Biol 2003; 23: 1674-1687. (Pubitemid 36246049)
225. Terry S, Yang X, Chen MW, Vacherot F, Buttyan R. Multifaceted interaction between the androgen and Wnt signaling pathways and the implication for prostate cancer. J Cell Biochem 2006; 99: 402-410. (Pubitemid 44435558)
226. Yang X, Chen MW, Terry S, Vacherot F, Bemis DL et al. Complex regulation of human androgen receptor expression by Wnt signaling in prostate cancer cells. Oncogene 2006; 25: 3436-3444. (Pubitemid 43877046)
227. Ulrix W, Swinnen JV, Heyns W, Verhoeven G. Androgens down-regulate the expression of the human homologue of paternally expressed gene-3 in the prostatic adenocarcinoma cell line LNCaP. Mol Cell Endocrinol 1999; 155: 69-76. (Pubitemid 29460966)
228. Plagge A, Gordon E, Dean W, Boiani R, Cinti S et al. The imprinted signaling protein XL alpha s is required for postnatal adaptation to feeding. Nat Genet 2004; 36: 818-826. (Pubitemid 39014098)
229. Plagge A, Kelsey G. Imprinting the Gnas locus. Cytogenet Genome Res 2006; 113: 178-187.
230. Plagge A, Kelsey G, Germain-Lee EL. Physiological functions of the imprinted Gnas locus and its protein variants Galpha(s) and XLalpha(s) in human and mouse. J Endocrinol 2008; 196: 193-214. (Pubitemid 351298506)
231. Sakamoto A, Liu J, Greene A, Chen M, Weinstein LS. Tissue-specific imprinting of the G protein Gsalpha is associated with tissue-specific differences in histone methylation. Hum Mol Genet 2004; 13: 819-828. (Pubitemid 38515211)
232. Kelsey G. Imprinting on chromosome 20: Tissue-specific imprinting and imprinting mutations in the GNAS locus.Am J Med Genet C Semin Med Genet 2010; 154C: 377-386.
233. Weinstein LS, Liu J, Sakamoto A, Xie T, Chen M. Minireview: GNAS: Normal and abnormal functions. Endocrinology 2004; 145: 5459-5464. (Pubitemid 39564584)
234. Mariot V, Wu JY, Aydin C, Mantovani G, Mahon MJ et al. Potent constitutive cyclic AMP-generating activity of XLalphas implicates this imprinted GNAS product in the pathogenesis of McCune-Albright syndrome and fibrous dysplasia of bone. Bone 2011; 48: 312-320.
235. Wilson CH, McIntyre RE, Arends MJ, Adams DJ. The activating mutation R201C in GNAS promotes intestinal tumourigenesis in Apc(Min/1) mice through activation of Wnt and ERK1/2 MAPK pathways. Oncogene 2010; 29: 4567-4575.
236. Kan Z, Jaiswal BS, Stinson J, Janakiraman V, Bhatt D et al. Diverse somatic mutation patterns and pathway alterations in human cancers. Nature 2010; 466: 869-873.
237. Middeldorp A, van Eijk R, Oosting J, Forte GI, van Puijenbroek M et al. Increased frequency of 20q gain and copy-neutral loss of heterozygosity in mismatch repair proficient familial colorectal carcinomas. Int J Cancer 2012; 130: 837-846.
238. Tominaga E, Tsuda H, Arao T, Nishimura S, Takano M et al. Amplification of GNAS may be an independent, qualitative, and reproducible biomarker to predict progression-free survival in epithelial ovarian cancer. Gynecol Oncol 2010; 118: 160-166.
239. Mantovani G, Lania AG, Spada A. GNAS imprinting and pituitary tumors. Mol Cell Endocrinol 2010; 326: 15-18.
240. Frey UH, Alakus H, Wohlschlaeger J, Schmitz KJ, Winde G et al. GNAS1 T393C polymorphism and survival in patients with sporadic colorectal cancer. Clin Cancer Res 2005; 11: 5071-5077. (Pubitemid 41003689)
241. Frey UH, Eisenhardt A, Lummen G, Rubben H, Jockel KH et al. The T393C polymorphism of the G alpha s gene (GNAS1) is a novel prognostic marker in bladder cancer. Cancer Epidemiol Biomarkers Prev 2005; 14: 871-877. (Pubitemid 40478550)
242. Alakus H, Monig SP, Warnecke-Eberz U, Alakus G, Winde G et al. Association of the GNAS1 T393C polymorphism with tumor stage and survival in gastric cancer. World J Gastroenterol 2009; 15: 6061-6067.
243. Frey UH, Lummen G, Jager T, Jockel KH, Schmid KW et al. The GNAS1 T393C polymorphism predicts survival in patients with clear cell renal cell carcinoma. Clin Cancer Res 2006; 12: 759-763. (Pubitemid 43259855)
244. Eisenhardt A, Scherag A, Jockel KH, Reis H, Rubben H et al. Lack of association of the genotype in the GNAS Fok I polymorphism and prostate cancer. Urol Int 2011; 87: 80-86.
245. Adany R, Heimer R, Caterson B, Sorrell JM, Iozzo RV. Altered expression of chondroitin sulfate proteoglycan in the stroma of human colon carcinoma. Hypomethylation of PG-40 gene correlates with increased PG-40 content and mRNA levels. J Biol Chem 1990; 265: 11389-96.
246. Gu Y, Zhang S, Wu Q, Xu S, Cui Y et al. Differential expression of decorin, EGFR and cyclin D1 during mammary gland carcinogenesis in TA2 mice with spontaneous breast cancer. J Exp Clin Cancer Res 2010; 29: 6.
247. Skandalis SS, Labropoulou VT, Ravazoula P, Likaki-Karatza E, Dobra K et al. Versican but not decorin accumulation is related to malignancy in mammographically detected high density and malignant-Appearing microcalcifications in non-palpable breast carcinomas. BMC Cancer 2011; 11: 314.
248. Schaefer L. Small leucine-rich proteoglycans in kidney disease. J Am Soc Nephrol 2011; 22: 1200-1207.
249. Hu Y, Sun H, Owens RT, Wu J, Chen YQ et al. Decorin suppresses prostate tumor growth through inhibition of epidermal growth factor and androgen receptor pathways. Neoplasia 2009; 11: 1042-1053.
250. Banerjee AG, Liu J, Yuan Y, Gopalakrishnan VK, Johansson SL et al. Expression of biomarkers modulating prostate cancer angiogenesis: Differential expression of annexin II in prostate carcinomas from India and USA. Mol Cancer 2003; 2: 34.
251. Nonn L, Ananthanarayanan V, Gann PH. Evidence for field cancerization of the prostate. Prostate 2009; 69: 1470-1479.
252. Dekel B, Metsuyanim S, Schmidt-Ott KM, Fridman E, Jacob-Hirsch J et al. Multiple imprinted and stemness genes provide a link between normal and tumor progenitor cells of the developing human kidney. Cancer Res 2006; 66: 6040-6049.
253. Yan Z, Choi S, Liu X, Zhang M, Schageman JJ et al. Highly coordinated gene regulation in mouse skeletal muscle regeneration. J Biol Chem 2003; 278: 8826-8836. (Pubitemid 36800642)
254. Ayesh B, Matouk I, Ohana P, Sughayer MA, Birman T, et al. Inhibition of tumor growth by DT-A expressed under the control of IGF2 P3 and P4 promoter sequences. Mol Ther 2003; 7: 535-541. (Pubitemid 36553423)
255. Warzee B, Mesnil C, Hober D, Caloone D, Pirottin D et al. Viral induction of Zac1b through TLR3- and IRF3-dependent pathways. Mol Immunol 2010; 48: 119-127.
256. Shibui T, Higo Y, Tsutsui TW, Uchida M, Oshimura M et al. Changes in expression of imprinted genes following treatment of human cancer cell lines with non-mutagenic or mutagenic carcinogens. Int J Oncol 2008; 33: 351-360.
257. Wang ZA, Shen MM. Revisiting the concept of cancer stem cells in prostate cancer. Oncogene 2011; 30: 1261-1271.
258. Feinberg AP, Ohlsson R, Henikoff S. The epigenetic progenitor origin of human cancer. Nat Rev Genet 2006; 7: 21-33. (Pubitemid 41828945)
259. Baylin SB, Ohm JE. Epigenetic gene silencing in cancer-A mechanism for early oncogenic pathway addiction? Nat Rev Cancer 2006; 6: 107-116. (Pubitemid 43361543)
260. Murrell A. Genomic imprinting and cancer: From primordial germ cells to somatic cells. Sci World J 2006; 6: 1888-1910.
261. Kaneda A, Wang CJ, Cheong R, Timp W, OnyangoP et al. Enhanced sensitivity to IGF-II signaling links loss of imprinting of IGF2 to increased cell proliferation and tumor risk. Proc Natl Acad Sci USA 2007; 104: 20926-31.